Eight other lawsuits winding their way through the courts don't involve providers, so even if they hit a roadblock, it likely won't be for the same reason.
Just 2,000 patients have been treated so far with Leqembi, Biogen said Tuesday, a warning that the Alzheimer's drug developed with Eisai Co. may miss its target of 10,000 recipients by the end of March.
Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.
Judge David Alan Ezra in the Western District of Texas granted the Biden administration's request to dismiss the lawsuit, ruling that the plaintiffs lacked standing.